EMH.V - Emerald Health Therapeutics, Inc.

TSXV - TSXV Delayed Price. Currency in CAD
4.2000
-0.2500 (-5.62%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close4.4500
Open4.3700
Bid4.1500 x 0
Ask4.2000 x 0
Day's Range4.1100 - 4.4200
52 Week Range2.0400 - 5.9200
Volume946,705
Avg. Volume974,734
Market Cap599.521M
Beta (3Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.1720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.15
  • GlobeNewswire3 days ago

    Emerald Health Therapeutics Applauds Government of Canada for Proposing Amendment to Cannabis Excise Tax in Federal Budget

    OTCQX: EMHTF) applauds the Government of Canada for proposing to amend the excise tax calculation for cannabis in the federal budget announced yesterday. The implementation of the proposed revision announced in the federal budget would result in the calculation of the excise duty of ingestible cannabis and hemp products being based on the quantity of THC in the products, as opposed to the current tax set in relation to the product volume.

  • GlobeNewswire5 days ago

    Emerald Health Therapeutics Appoints Vice President, Communications and Stakeholder Relations

    OTCQX:EMHTF) announced today that Allan Rewak has been appointed Vice President, Communications and Stakeholder Relations, effective April 15, 2019. Prior to joining Emerald, Mr. Rewak was the Executive Director at the Cannabis Council of Canada (C3), Canada’s national industry association for cannabis, cultivators and processors. For his work, the Financial Post named him “One of the 20 Power Players Setting Down Roots in the Cannabis Industry”.

  • Market Exclusive8 days ago

    Emerald Health Increases Sales After Fulfilling Ontario Cannabis Purchase Order

    Emerald Health Therapeutics Inc. (OTCMKTS:EMHTF) has indicated that it has finalised its first cannabis purchase order from the Ontario Cannabis Retail Corporation that operates as Ontario Cannabis Store. Expanding supply to other provinces through OCS Emerald Executive Chairman and President, Dr. Avtar Dillon, indicated that the company is scaling up its production in the wholly-owned […]The post Emerald Health Increases Sales After Fulfilling Ontario Cannabis Purchase Order appeared first on Market Exclusive.

  • GlobeNewswire9 days ago

    Emerald Health Therapeutics Continues to Grow Sales with First Cannabis Shipment to Ontario Cannabis Retail Corporation

    OTCQX:EMHTF) has fulfilled its first purchase order of cannabis from Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”). “As we scale up production in our wholly-owned, premium indoor growing facility, Verdélite, and our large-scale, state-of-the-art joint venture greenhouse operation, Pure Sunfarms, we are consistently meeting our supply commitments of Emerald-branded adult-use cannabis in British Columbia and Newfoundland Labrador, and we are now prepared to provide the same service to the Ontario Cannabis Retail Corporation and other provinces,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. Currently, Emerald’s cannabis supply is provided primarily through its 88,000 sq. ft. Verdélite indoor facility in Saint Eustache, Quebec, and through Pure Sunfarms, its 50%-owned 1.1 million sq. ft. greenhouse facility in Delta, British Columbia.

  • Market Exclusive11 days ago

    Emerald Health Announces Joint Venture With Pure Sunfarms With 1M Sq Ft of Space

    Emerald Health Therapeutics Inc. (OTCMKTS:EMHTF) has announced that Health Canada has granted pure Sunfarms Corp its seventh amendment for the cultivation license of its Delta BC greenhouse. Emerald owns 50% of the low cost, large-scale cannabis production company. Additional cultivation space licensed In addition to the 1.1 million square foot Delta BC greenhouse, the company […]The post Emerald Health Announces Joint Venture With Pure Sunfarms With 1M Sq Ft of Space appeared first on Market Exclusive.

  • GlobeNewswire11 days ago

    Cannabis Stocks That Could See Significant Growth in Retail

    Cannabis sales have been soaring since legalization in Canada but there's a lot more to come as the industry continues to change. Here are some of the hottest cannabis stocks right now that are positioning themselves to take advantage of the fast-growing retail market. Westleaf has been making a name for itself in the industry as it looks to become a dominant force in the retail market.

  • GlobeNewswire12 days ago

    Emerald Health Therapeutics Sees Pure Sunfarms Licensed for 1.03 Million Square Feet of Cannabis Cultivation; Full Planting Targeted for End of April

    OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), received from Health Canada its seventh amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 206,000 square feet of growing area in the fourth and final quadrant of the greenhouse brings Pure Sunfarms’ total licensed cannabis production area to approximately 1.03 million sq. ft. in 16 grow rooms. “Pure Sunfarms is now licensed across all its growing areas and we congratulate their team for this significant accomplishment,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “With Emerald’s 50% stake in one of the largest fully operational cannabis production facilities in the world, we expect to realize significant economic value from Pure Sunfarms.

  • GlobeNewswire16 days ago

    Emerald Health Therapeutics’ Licensed Endo Product Wins Taste For Life’s 2019 Essentials Supplement Award in the U.S.

    OTCQX:EMHTF)  today announced that its joint venture partner’s, (Emerald Health Bioceuticals or “EHB”), Endo Bliss, won Taste For Life’s 2019 Essentials Supplement Award, which recognizes the most outstanding natural supplements in health and wellness in the U.S. Emerald will launch the Endo product line in Canada in 2019 through its joint venture, Emerald Health Naturals (“EHN”), which secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (“ECS”), but which does not contain cannabis.

  • Barrons.com25 days ago

    5 Marijuana Stocks to Buy — and 2 to Avoid, According to an Analyst

    Five cannabis stocks got a thumbs-up from Jefferies, as the firm started coverage of Canadian marijuana producers.

  • ACCESSWIRElast month

    Four Pot Stocks Looking To Close Out a Strong Week

    CORAL GABLES, FL / ACCESSWIRE / February 21, 2019 / The 2019 year has already shown a significant amount of upward momentum for the marijuana stock market. A key reason for this tidal shift of positive energy is due to the fact that companies throughout the industry are progressing because many states in the U.S., as well as Canada, have passed legislation in favor of legalizing cannabis. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Emerald Health Therapeutics Inc (EMHTF) (TSX-VEMH), CannTrust Holdings Inc (OTC PINK: CNTTF), and KushCo Holdings Inc (KSHB) are 4 pot stocks that could test this week's highs.

  • ACCESSWIRElast month

    Watch These Marijuana Stocks Push Their Limits

    Generations earlier, many people believed cannabis to be a harmful substance and demanded that the federal government keep it out of the hands of consumers, but as we've come to understand, cannabis has a myriad of health benefits and is nothing to be afraid of. Over the past few years, cannabis companies have continued to release new products with medical cannabis for the purpose of improving the quality of treatment options available for consumers in the healthcare space. ), Aphria Inc (APHA), Emerald Health Therapeutics Inc (EMHTF) (EMH.V) and Tilray Inc (TLRY) are four companies that could test February highs.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Launches 88,000 Square Foot State-of-the-Art, Fully-Integrated Indoor Facility and Verdélite Brand in Québec

    OTCQX: EMHTF) today announced the launch of Verdélite Sciences Inc. ("Verdélite"), a wholly-owned, Québec-based production subsidiary licensed by Health Canada. Formerly known as Agro-Biotech, Verdélite currently produces high-grade dried cannabis for medical and adult-use purposes. Emerald is nearing completion of its over $100 million investment to secure and expand its multi-purpose facility to 88,000 square feet and enable the complete cycle of indoor cultivation, product development and automated packaging of cannabis products.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Announces Completion of Pure Sunfarms CAD$20 Million Credit Facility with Bank of Montreal and Farm Credit Canada

    OTCQX:EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms Corp. (“Pure Sunfarms”), has entered into a credit agreement with Bank of Montreal (“BMO”) as agent and lead lender and Farm Credit Canada (“FCC”) as lender (together with BMO, the “Lenders”) in respect of a CAD$20 million secured non-revolving term loan (the “Credit Facility”). Pure Sunfarms intends to use the funds available under the Credit Facility to finance the final costs of converting its 1.1 million square foot greenhouse for cannabis production, the vast majority of which was completed in January of this year. The funds available under the Credit Facility may also be used for general corporate purposes.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Announces Pure Sunfarms’ Selection to Supply Ontario Cannabis Store

    OTCQX:EMHTF) today announced its cannabis joint venture, Pure Sunfarms Corp. (“Pure Sunfarms”), has through a competitive process been selected by and entered into a supply agreement with the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store (“OCS”), to supply the OCS with Pure Sunfarms-branded cannabis products for the non-medical market in the Province of Ontario.

  • ACCESSWIRElast month

    Watch These Marijuana Stocks Enjoy A Boost From Today's Headlines

    As we see an increase in agricultural technology being used to increase the yield, and quality, of cannabis products, companies across the space will have greater access to inventory to distribute their products. Considering the fact that legal marijuana is becoming a reality in a large portion of the United States, Canada, and abroad, investors that have historically written off cannabis companies, are now flocking in droves with excitement. Nabis Holdings (INNPF) (NAB), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Green Growth Brands Inc (GGBXF), and The Supreme Cannabis Company (SPRWF) are four cannabis companies worth keeping on your radar on Thursday.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Secures Proprietary Extraction Technology and  Extraction Capabilities in Agreement with Indena

    OTCQX:EMHTF) has entered into a license with Indena S.p.A. (“Indena”) of Milan, Italy, bearing certain exclusivity rights in Canada to use Indena’s cannabidiol (“CBD”) extraction technology, and contract manufacturing services for CBD extraction. In addition, Emerald has obtained exclusive use of Indena’s proprietary Phytosome® technology for the purpose of developing novel cannabinoid-based products with superior utility, subject to a minimum volume agreement.

  • ACCESSWIRE2 months ago

    These 4 Marijuana Stocks Could Surpass Investor Expectations

    CORAL GABLES, FL / ACCESSWIRE / February 4, 2019 / Marijuana stocks have managed to become one of the hottest topics in the news over the course of the past few years. The fact of the matter is that previously conceived notions on cannabis are being replaced by favorable public opinions supporting all possible uses of marijuana, namely as a means of treatment for patients suffering from a myriad of ailments. Global Consortium Inc (GCGX), Emerald Health Therapeutics Inc (EMHTF) (EMH.V), Trulieve Cannabis Corp (OTC PINK: TCNNF), and OrganiGram Holdings Inc (OGRMF) are four pot stocks looking to remain on high this month.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Discharge of Litigation

    OTCQX:EMHTF) announced today that its wholly-owned subsidiary, Verdélite Sciences Inc. (“Verdélite”), which operates a 75,000 square foot indoor cannabis cultivation facility in St.-Eustache, Quebec, has entered into a release, discharge and transaction agreement settling all claims made by Pivot Pharmaceuticals Inc. (“Pivot”) against Verdélite and its former shareholders, as described in Emerald’s most recent MD&A. The claims relate to a non-binding letter of intent which Verdélite and its former shareholders had previously entered into with Pivot with respect to a potential sale of Verdélite.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US

    OTCQX:EMHTF)  today announced that its joint venture partner, San Diego-based Emerald Health Bioceuticals (“EHB”), has launched its award-winning Endo products in Whole Foods Markets across the United States, highlighting the unique positioning and opportunity for this product line when it is launched in Canada in 2019.  The joint venture, called Emerald Health Naturals (“EHN”), secured Canadian distribution rights for this product line that was developed to support the body’s endocannabinoid system (ECS), but which does not contain cannabis. Canadian retailers have not been announced.

  • GlobeNewswire2 months ago

    Emerald Health sees Expansion of Pure Sunfarms’ Cannabis Cultivation License to 825,000 Square Feet

    OTCQX:EMHTF) announced that its 50%-owned joint venture focused on large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada its sixth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. The additional approximately 138,000 square feet brings Pure Sunfarms’ total licensed cannabis production area to approximately 825,000 square feet. The newly licensed area is expected to be fully planted and in production this week.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Secondary Offering

    Emerald Health Therapeutics, Inc. (EMH.V) (“Emerald” or the “Company”) today announced that Emerald Health Sciences Inc. (the “Selling Shareholder”) has entered into a share purchase agreement (the “Share Purchase Agreement”) with a single Canadian institutional accredited investor (the “Investor”) in connection with a secondary offering (the “Secondary Offering”) of common shares of the Company. Pursuant to the Share Purchase Agreement, the Investor will purchase 2,800,000 common shares of the Company (the “Secondary Shares”) from the Selling Shareholder at a price of $2.50 per Secondary Share.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Closes Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that, further to its news releases dated April 17, 2018 and November 19, 2018, it has closed its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), called Emerald Health Naturals (“EHN”).

  • ACCESSWIRE3 months ago

    Today's Research Reports on TSO3, Emerald Health Therapeutics, DiaMedica Therapeutics and Nuvo Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 4, 2019 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...